Citadel Advisors
SCMP

Citadel Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Citadel Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-61,524
Closed -$834K – 8420
2016
Q4 		$834K Buy
61,524
+27,433
+80% +$383K ﹤0.01% 4114
2016
Q3 		$420K Buy
+34,091
New +$402K ﹤0.01% 5134
2016
Q1 		– Sell
-7,473
Closed -$94.4K – 8749
2015
Q4 		$129K Sell
7,473
-3,964
-35% -$71.1K ﹤0.01% 6406
2015
Q3 		$227K Buy
+11,437
New +$262K ﹤0.01% 5980
2015
Q2 		– Sell
-92,596
Closed -$1.44M – 9322
2015
Q1 		$1.44M Buy
92,596
+5,858
+7% +$90.8K ﹤0.01% 3487
2014
Q4 		$1.24M Buy
86,738
+40,210
+86% +$425K ﹤0.01% 3495
2014
Q3 		$302K Sell
46,528
-19,169
-29% -$127K ﹤0.01% 5254
2014
Q2 		$453K Sell
65,697
-38,359
-37% -$271K ﹤0.01% 4530
2014
Q1 		$744K Buy
104,056
+71,545
+220% +$612K ﹤0.01% 3811
2013
Q4 		$306K Sell
32,511
-10,776
-25% -$76.9K ﹤0.01% 4587
2013
Q3 		$270K Buy
43,287
+33,019
+322% +$206K ﹤0.01% 4475
2013
Q2 		$68K Buy
+10,268
New +$81.5K ﹤0.01% 5487

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Citadel Advisors's SCMP Position: Q1 2017 in Review

Citadel Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2017, closing a stake of 61,524 shares — an estimated $834K sold.

Citadel Advisors first reported a position in SCMP in Q2 2013 and held it in 12 quarters. The position peaked at $1.44M in Q1 2015. 167 funds tracked by Wall St. Rank hold SCMP as of Q1 2017.

  • Citadel Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Citadel Advisors sold 61,524 Sucampo Pharmaceuticals, Inc. shares in Q1 2017, an estimated $834K.
  • Citadel Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
  • Citadel Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $1.44M in Q1 2015.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2017.

Based on Citadel Advisors's 13F filing for Q1 2017, filed 12 May 2017.